Shire plc Result of AGM

 
TIDMSHP 
 
Result of the 2017 Annual General Meeting 
 
April 25, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces 
that, at its Annual General Meeting held at The Merrion Hotel, Upper Merrion 
Street, Dublin 2, Ireland at 2.45pm today, all resolutions contained in the 
Notice of Meeting were decided by poll vote. The results of the poll are as 
follows: 
 
Resolutions                    For         %       Against      %       Votes    Withheld 
                           (including                                 cast as a 
                          discretionary                                 % of 
                             votes)                                   relevant 
                                                                      shares in 
                                                                        issue 
 
Ordinary Resolutions 
 
1. To receive the          654,818,375   98.84%   7,707,875   1.16%    73.04%   4,881,183 
Company's Annual Report 
and Accounts for the year 
ended December 31, 2016. 
 
2. To approve the          615,163,095   93.22%  44,723,057   6.78%    72.75%   7,521,281 
Directors' Remuneration 
Report. 
 
3. To re-elect Dominic     649,117,820   98.05%  12,928,333   1.95%    72.99%   5,361,280 
Blakemore as a Director. 
 
4. To re-elect Olivier     627,642,447   94.87%  33,920,776   5.13%    72.94%   5,844,210 
Bohuon as a Director. 
 
5. To re-elect William     665,784,255   99.86%    960,666    0.14%    73.51%    662,512 
Burns as a Director. 
 
6. To elect Ian Clark as   651,027,149   97.63%  15,797,431   2.37%    73.52%    582,853 
a Director. 
 
7. To elect Gail Fosler    661,335,866   99.18%   5,499,058   0.82%    73.52%    572,509 
as a Director. 
 
8. To re-elect Steven      635,977,566   95.40%  30,649,403   4.60%    73.50%    780,464 
Gillis as a Director. 
 
9. To re-elect David       666,231,111   99.91%    593,588    0.09%    73.52%    582,734 
Ginsburg as a Director. 
 
10. To re-elect Susan      659,834,334   99.01%   6,565,404   0.99%    73.47%   1,007,695 
Kilsby as a Director. 
 
11. To re-elect Sara       660,030,658   98.98%   6,802,836   1.02%    73.52%    573,939 
Mathew as a Director. 
 
12. To re-elect Anne       657,515,406   99.31%   4,576,118   0.69%    73.00%   5,315,909 
Minto as a Director. 
 
13. To re-elect Flemming   666,498,607   99.95%    322,419    0.05%    73.52%    586,407 
Ornskov as a Director. 
 
14. To re-elect Jeffrey    663,597,002   99.51%   3,236,158   0.49%    73.52%    574,273 
Poulton as a Director. 
 
 
 
15. To elect Albert        660,769,699   99.09%   6,047,544   0.91%    73.52%    590,190 
Stroucken as a Director. 
 
16. To re-appoint          596,710,936   89.64%  68,985,657   10.36%   73.39%   1,710,840 
Deloitte LLP as the 
Company's Auditor. 
 
17. To authorize the       613,970,704   92.24%  51,651,020   7.76%    73.39%   1,785,709 
Audit, Compliance & Risk 
Committee to determine 
the remuneration of the 
Auditor. 
 
18. To authorize the       622,880,755   93.40%  43,989,439   6.60%    73.52%    537,239 
allotment of shares. 
 
Special Resolutions 
 
19. To authorize the       647,605,695   97.72%  15,078,442   2.28%    73.06%   4,723,296 
general disapplication of 
pre-emption rights. 
 
20. To authorize the       632,770,742   95.48%  29,932,382   4.52%    73.06%   4,704,309 
specific disapplication 
of pre-emption rights. 
 
21. To authorize           658,828,861   98.87%   7,499,007   1.13%    73.46%   1,079,565 
purchases of own shares. 
 
22. To adopt new Articles  660,636,265   99.08%   6,130,317   0.92%    73.51%    640,851 
of Association. 
 
23. To approve the notice  619,638,682   93.34%  44,232,588   6.66%    73.19%   3,536,163 
period for general 
meetings. 
 
As at the record date, April 23, 2017, the Company had 907,025,186 Ordinary 
Shares of 5 pence each in issue (excluding shares held in treasury). 
Shareholders are entitled to one vote per share. A vote "withheld" is not a 
vote in law and is not counted in the calculation of the proportion of votes 
validly cast. 
 
In accordance with Listing Rule 9.6.2R, copies of the relevant resolutions 
passed at the meeting have been submitted to the National Storage Mechanism and 
will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm. 
 
Oliver Strawbridge 
Senior Assistant Company Secretary 
 
For further information please contact: 
 
Investor Relations 
 
Ian Karp                        [e-mail]            [phone] 
 
Robert Coates                   [e-mail]          [phone] 
 
Media 
 
Lisa Adler                      [e-mail]       [phone] 
 
Debbi Ford                      [e-mail]       [phone] 
 
NOTES TO EDITORS 
 
About Shire 
 
Shire is the leading global biotechnology company focused on serving people 
with rare diseases. We strive to develop best-in-class products, many of which 
are available in more than 100 countries, across core therapeutic areas 
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage 
Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary 
Angioedema; and a growing franchise in Oncology. 
 
Our employees come to work every day with a shared mission: to develop and 
deliver breakthrough therapies for the hundreds of millions of people in the 
world affected by rare diseases and other high-need conditions, and who lack 
effective therapies to live their lives to the fullest. 
 
www.shire.com 
 
 
 
END 
 

(END) Dow Jones Newswires

April 25, 2017 11:15 ET (15:15 GMT)